top of page


Is Retatrutide Better Than Tirzepatide? What We Know and Don’t Know
Weight management medicine is moving faster than almost any other field in clinical practice. Just a few years ago, the best pharmacological tools available for obesity offered 5–8% total body weight loss. Then tirzepatide arrived, and suddenly 20% was achievable. Now, early data on retatrutide — a drug that adds a third receptor target to the formula — is pushing that figure higher still. But “higher numbers” in a Phase 2 trial and “better medicine” for your patients are not

Jan Medical Group
Oct 277 min read


Why Physician Supervision Matters When Using Tirzepatide or Semaglutide for Weight Loss
GLP-1 receptor agonists have changed the conversation around weight management more dramatically than any class of medication in decades. Tirzepatide and semaglutide, the active compounds behind Mounjaro, Zepbound, Ozempic, and Wegovy, produce weight loss outcomes once achievable only through bariatric surgery. Clinical trials have shown total body weight reductions of 15 to 22 percent, and for millions of people living with obesity or metabolic disease, that is genuinely lif

Jan Medical Group
Aug 89 min read
bottom of page
